title: Intravesical Bacillus Calmette-Guérin treatment for superficial bladder tumours.
abstract: Intravesical instillations of Tokyo 172 strain BCG were given to 56 patients with superficial bladder cancer during the 24-month period after transurethral tumour resection as a prophylaxis against tumour recurrence. The recurrence rate of tumours was compared with that of historical controls. Results were estimated by the person-years method and there were statistically significant decreases in recurrent tumours following BCG therapy. Our results suggest that the intravesical Tokyo 172 strain BCG is effective and safe as a prophylaxis against the recurrence of superficial bladder tumours.
authors.affiliation: Department of Urology, Wakayama Medical College, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shinka
authors.forename: A
authors.initials: A
authors.lastname: Hirano
authors.forename: Y
authors.initials: Y
authors.lastname: Uekado
authors.forename: I
authors.initials: I
authors.lastname: Kyoku
authors.forename: H
authors.initials: H
authors.lastname: Aoshi
authors.forename: T
authors.initials: T
authors.lastname: Ohkawa
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine